📊 Income Statement

Revenue by Product

TherapeuticsDiagnostics
01M2M4M5M6M8M9M10MQ3 2025Q4 2025Q1 2026Q2 2026Q3 2026

Revenue by Geography

UNITED STATESNon-US
01M2M3M4M6M7M8M9MQ3 2025Q4 2025Q1 2026Q2 2026Q3 2026

Revenue, Gross Profit, Operating and Net Income

RevenueGross ProfitOperating IncomeNet Income
02M5M8M10M12M15M18M20MQ3 2025Q4 2025Q1 2026Q2 2026Q3 2026

Margin (%)

Gross MarginOperating MarginNet Income Margin
0255075100125150175200Q3 2025Q4 2025Q1 2026Q2 2026Q3 2026

Operating Expenses

Research And Development ExpensesSelling And Marketing ExpensesGeneral And Administrative ExpensesOther Expenses
05M10M15M20M25M30M35M40MQ3 2025Q4 2025Q1 2026Q2 2026Q3 2026

EBITDA

EBITDA
-80M-70M-60M-50M-40M-30M-20M-10M1Q3 2025Q4 2025Q1 2026Q2 2026Q3 2026

EPS

Revenue Variation (%)

Revenue Variation
-30-24-18-11-5181420Q3 2025Q4 2025Q1 2026Q2 2026Q3 2026

Income Variation (%)

Gross Profit VariationOperating Income VariationNet Income Variation
02505007501K1K2K2K2KQ3 2025Q4 2025Q1 2026Q2 2026Q3 2026

Revenue YoY Variation (%)

Revenue YoY Variation
02581012151820Q3 2025Q4 2025Q1 2026Q2 2026Q3 2026

Income YoY Variation (%)

Gross Profit YoY VariationOperating Income YoY VariationNet Income YoY Variation
02505007501K1K2K2K2KQ3 2025Q4 2025Q1 2026Q2 2026Q3 2026

Price-to-Earning Ratio

P/E Ratio
-6-5-4-3-2-2-101Q3 2025Q4 2025Q1 2026Q2 2026

Income Breakdown

Operating IncomeInterest IncomeTotal Other Income Expenses NetNet Income
04M8M11M15M19M22M26M30MQ3 2025Q4 2025Q1 2026Q2 2026Q3 2026

Per Share Metrics

Revenue Per ShareNet Income Per ShareOperating Cash Flow Per Share
000001111Q3 2025Q4 2025Q1 2026Q2 2026Q3 2026

Expense Ratios

Research And Ddevelopement To RevenueCapex To RevenueStock Based Compensation To Revenue
000001111Q3 2025Q4 2025Q1 2026Q2 2026Q3 2026
💰 Cash Flow Statement

Operating Cash Flow

Free Cash Flow

Cash At End Of Period
02M5M8M10M12M15M18M20MQ3 2025Q4 2025Q1 2026Q2 2026Q3 2026

Cash Flow to Debt Ratio

🏦 Balance Sheet
📈 Key Metrics